Literature DB >> 19492200

Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity.

Amélie Cartier1, Jean Bergeron, Paul Poirier, Natalie Alméras, Angelo Tremblay, Isabelle Lemieux, Jean-Pierre Després.   

Abstract

BACKGROUND: Adipose tissue (AT) is an important source of interleukin-1 receptor antagonist (IL-1Ra). Its expression is markedly increased in obesity. AIMS AND METHODS: To quantify the associations of IL-1Ra with body fat distribution as well as to examine the respective contributions of IL-1Ra and visceral adiposity to the variation in some cardiometabolic risk (CMR) markers. Plasma IL-1Ra levels were measured in a sample of 117 healthy non-diabetic men (age: 44.9+/-10.1 years; body mass index (BMI): 28.8+/-4.5 kg/m(2)).
RESULTS: Plasma IL-1Ra levels correlated positively with BMI, waist girth, and visceral and subcutaneous AT (0.39 < or = r<0.48; P < 0.0001). Multiple regression analyses revealed that visceral AT was the best independent predictor of IL-1Ra levels, explaining 22% (P < 0.0001) of its variance. IL-1Ra (P < 0.05) was an independent predictor of several CMR markers including triglyceride and high-density lipoprotein (HDL) cholesterol levels, cholesterol/HDL cholesterol ratio, glucose and insulin concentrations in response to a 75 g oral glucose load, and fasting insulin levels, in addition to the expected contribution of visceral AT (P < 0.05).
CONCLUSIONS: These results suggest that elevated IL-1Ra concentrations are influenced to a greater extent by visceral than subcutaneous adiposity and that IL-1Ra is independently related to some features of CMR beyond the known contribution of visceral adiposity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19492200     DOI: 10.1080/07853890903022801

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  11 in total

1.  Genome-wide associated loci influencing interleukin (IL)-10, IL-1Ra, and IL-6 levels in African Americans.

Authors:  Fasil Tekola Ayele; Ayo Doumatey; Hanxia Huang; Jie Zhou; Bashira Charles; Michael Erdos; Jokotade Adeleye; Williams Balogun; Olufemi Fasanmade; Thomas Johnson; Johnnie Oli; Godfrey Okafor; Albert Amoah; Benjamin A Eghan; Kofi Agyenim-Boateng; Joseph Acheampong; Clement A Adebamowo; Alan Herbert; Norman Gerry; Michael Christman; Guanjie Chen; Daniel Shriner; Adebowale Adeyemo; Charles N Rotimi
Journal:  Immunogenetics       Date:  2011-12-29       Impact factor: 2.846

2.  Urine chemokines indicate pathogenic association of obesity with BPH/LUTS.

Authors:  Pradeep Tyagi; Saundra S Motley; Mahendra Kashyap; Subrata Pore; Jeffrey Gingrich; Zhou Wang; Naoki Yoshimura; Jay H Fowke
Journal:  Int Urol Nephrol       Date:  2015-04-30       Impact factor: 2.370

Review 3.  Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression.

Authors:  Richard C Shelton; Andrew H Miller
Journal:  Prog Neurobiol       Date:  2010-04-22       Impact factor: 11.685

4.  Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study.

Authors:  Maren Carstensen; Christian Herder; Mika Kivimäki; Markus Jokela; Michael Roden; Martin J Shipley; Daniel R Witte; Eric J Brunner; Adam G Tabák
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

Review 5.  Environmental perturbations: Obesity.

Authors:  Stephanie A Shore
Journal:  Compr Physiol       Date:  2011-01       Impact factor: 9.090

6.  Adipose tissue-related proteins locally associated with resolution of inflammation in obese mice.

Authors:  Z M Jilkova; M Hensler; D Medrikova; P Janovska; O Horakova; M Rossmeisl; P Flachs; H Sell; J Eckel; J Kopecky
Journal:  Int J Obes (Lond)       Date:  2013-06-12       Impact factor: 5.095

7.  The systemic immune network in recent onset type 1 diabetes: central role of interleukin-1 receptor antagonist (DIATOR Trial).

Authors:  Hubert Kolb; Kathrin Lückemeyer; Tim Heise; Christian Herder; Nanette C Schloot; Wolfgang Koenig; Lutz Heinemann; Stephan Martin
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

8.  Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial).

Authors:  Alexander Strom; Hubert Kolb; Stephan Martin; Christian Herder; Marie-Christine Simon; Wolfgang Koenig; Tim Heise; Lutz Heinemann; Michael Roden; Nanette C Schloot
Journal:  PLoS One       Date:  2012-03-20       Impact factor: 3.240

9.  Serum IL-1 Receptor Antagonist Concentrations Associate With Unfavorable Metabolic Features in 12-Year-Old Children.

Authors:  Satu Seppä; Sirpa Tenhola; Raimo Voutilainen
Journal:  J Endocr Soc       Date:  2018-07-04

10.  Plasma IL-1Ra: linking hyperapoB to risk factors for type 2 diabetes independent of obesity in humans.

Authors:  S Bissonnette; N Saint-Pierre; V Lamantia; Y Cyr; H Wassef; M Faraj
Journal:  Nutr Diabetes       Date:  2015-09-28       Impact factor: 5.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.